Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy

Wu, Guicun; Wang, Zuozhi; Bian, Xiaoshan; Du, Xiliang; Wei, Changhong

doi:10.3109/13880209.2013.874533

Cited by 14 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to abnormal leaky (new or neo) vasculature and impaired lymphatic drainage, small non targeted particles (<400 nm) circulating in the blood tend to accumulate in the interstitial space of tumors and inflamed tis- [121][122][123][124][125][126][127][128][129][130] sues, a known hallmark of cancer (Fig. 2) [3].…”

Section: Passive Targetingmentioning

confidence: 99%

Design of liposomal formulations for cell targeting

Nogueira

Gomes

Preto

et al. 2015

Colloids and Surfaces B: Biointerfaces

144

103

View full text Add to dashboard Cite

Liposomes have gained extensive attention as carriers for a wide range of drugs due to being both nontoxic and biodegradable as they are composed of substances naturally occurring in biological membranes. Active targeting for cells has explored specific modification of the liposome surface by functionalizing it with specific targeting ligands in order to increase accumulation and intracellular uptake into target cells. None of the Food and Drug Administration-licensed liposomes or lipid nanoparticles are coated with ligands or target moieties to delivery for homing drugs to target tissues, cells or subcellular organelles. Targeted therapies (with or without controlled drug release) are an emerging and relevant research area. Despite of the numerous liposomes reviews published in the last decades, this area is in constant development. Updates urgently needed to integrate new advances in targeted liposomes research. This review highlights the evolution of liposomes from passive to active targeting and challenges in the development of targeted liposomes for specific therapies.

show abstract

Section: Passive Targetingmentioning

confidence: 99%

Design of liposomal formulations for cell targeting

Nogueira

Gomes

Preto

et al. 2015

Colloids and Surfaces B: Biointerfaces

144

103

View full text Add to dashboard Cite

show abstract

“…The average particle size was expressed as volume mean diameter and the reported value was represented as mean ± SD (n ¼ 3). The drug-loading ability (DL) encapsulation efficiency (EE) of the Bn-DOX/SLNs and DOX/SLNs were determined by a subtraction method (Wu et al, 2014). Briefly, 0.2 ml of SLNs complexes solution was centrifuged through a filter (EMD Millipore, Billerica, MA) with molecular weight cutoff of 3 kDa.…”

Section: Physicochemical Characterization Of Slnsmentioning

confidence: 99%

Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers

et al. 2015

View full text Add to dashboard Cite

Context: Breast cancer is the most common cancer in female population. Breast cancer chemotherapy using doxorubicin (DOX) is well illustrated. However, a significant obstacle for successful chemotherapy with DOX is multidrug resistant (MDR) in breast cancer cells. Targeted nanocarriers have emerged as frontier research for the improvement of cancer chemotherapy. Objective: Bombesin (Bn)-modified, DOX-loaded solid lipid nanoparticles (Bn-DOX/SLNs) were constructed. Doxorubicin-resistant MCF-7/MDR human breast cancer cells and the cancer animal models were applied for the evaluation of the in vitro and in vivo anti-tumor effect of Bn-DOX/SLNs. Methods: Bn-conjugated lipids were synthesized. DOX was then loaded into Bn-modified SLNs. The physicochemical properties of the Bn-DOX/SLNs were investigated by particle size and zeta potential measurement, drug loading and drug-entrapment efficiency, and in vitro drug release behavior. In vitro cytotoxicity against MCF-7/MDR cells was investigated, and in vivo anti-tumor of SLNs was evaluated in human breast cancer mice models. Results: Bn-DOX/SLNs showed an excellent in vitro cytotoxicity and in vivo anti-tumor effect both in MCF-7/MDR breast cancer cells and breast cancer animal model. Conclusion:The results demonstrated that Bn-DOX/SLNs reversed the resistance of doxorubicin, suggesting that chemotherapy using this kind of targeted nanocarriers may benefit human breast MDR cancer therapy.

show abstract

“…Actively targeted systems were thought to directly address the shortcoming of inefficient cellular uptake of passively targeted systems [14, 18]. Numerous targeting ligands have been utilized to actively target nanoparticles to cancer cells, including antibodies and antibody fragments [39, 40], aptamers [41], peptides [42], proteins, sugars [43], and low molecular weight ligands such as folate [44]. For excellent reviews of the features and design of actively targeted systems, please refer to [1, 18, 38, 45]…”

Section: Conventional Cancer Targeting Strategies: Active Targetingmentioning

confidence: 99%

Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery

Yang

Parker

McCallen

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Tumors are frequently characterized by genomically and phenotypically distinct cancer cell subpopulations within the same tumor or between tumor lesions, a phenomenon termed tumor heterogeneity. These diverse cancer cell populations pose a major challenge to targeted delivery of diagnostic and/or therapeutic agents, as the conventional approach of conjugating individual ligands to nanoparticles is often unable to facilitate intracellular delivery to the full spectrum of cancer cells present in a given tumor lesion or patient. As a result, many cancers are only partial suppressed, leading to eventual tumor regrowth and/or the development of drug-resistant tumors. Pretargeting (multistep targeting) approaches, which involves administering 1) a cocktail of bispecific proteins that can collectively bind to the entirety of a mixed tumor population followed by 2) nanoparticles containing therapeutic and/or diagnostic agents that can bind to the bispecific proteins accumulated on the surface of target cells offers the potential to overcome many of the challenges associated with drug delivery to heterogeneous tumors. Despite its considerable success in improving the efficacy of radioimmunotherapy, the pretargeting strategy remains underexplored for a majority of nanoparticle therapeutics applications, especially for targeted delivery to heterogeneous tumors. In this review, we will present concepts in tumor heterogeneity, the shortcomings of conventional targeted systems, lessons learned from pretargeted radioimmunotherapy, and important considerations for harnessing the pretargeting strategy to improve nanoparticle delivery to heterogeneous tumors.

show abstract

Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy

Cited by 14 publications

References 17 publications

Design of liposomal formulations for cell targeting

Design of liposomal formulations for cell targeting

Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers

Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery

Contact Info

Product

Resources

About